D. Bissett

Medicine · Health Sciences

26h-index2.7kcitations71works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(12), Skin Protection and Aging(11), Lung Cancer Treatments and Mutations(5), melanin and skin pigmentation(5), Neutropenia and Cancer Infections(5)

Publications71 total

Practicing During the COVID-19 Pandemic: Experiences of Canadian Hospital-Based Occupational Therapists
Canadian Journal of Occupational Therapy·2024· 1 cited
Hyperpigmentation in Aging Skin
2015· 1 cited
Hyperpigmentation in Aging Skin
2015
172 A case for development of stereotactic ablative body radiotherapy (SABR) for lung cancer at Aberdeen
Lung Cancer·2013
Endobronchial ultrasound guided transbronchial needle aspiration: a novel way to diagnose metastatic urological cancer
QJM·2012Open Access
A difficult diagnosis
QJM·2011Open Access
A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer.
Journal of Clinical Oncology·2011· 13 cited
391 A phase I clinical trial of CXR1002 in patients (pts) with advanced cancer
European Journal of Cancer Supplements·2010· 1 citedOpen Access
123 Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action
European Journal of Cancer Supplements·2010· 8 cited
Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and <i>N</i>-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial
British Journal of Dermatology·2009· 76 cited
Docetaxel first line use in advanced NSCLC
Lung Cancer·2008
Erlotinib use in NSCLC: how are we getting on?
Lung Cancer·2008
Do nurses do it better? An evaluation of nurse led follow up clinic for lung cancer (NLFLC)
Lung Cancer·2008
First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action
British Journal of Cancer·2007· 20 citedOpen Access
P-104 Identification of the lysosomal programmed cell death (PCD)pathway as a critical determinant of clinical response in Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer·2005
Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin<sup>1</sup>
International Journal of Cosmetic Science·2005· 195 cited
Rhabdomyolysis in prostate cancer – caution in prescribing cyproterone acetate with statins
Clinical Oncology·2004· 2 cited
Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin<sup>1</sup>
International Journal of Cosmetic Science·2004· 180 cited
Molecular profiling of response to platinum based therapy in non-small cell lung cancer (NSCLC) patients
Journal of Clinical Oncology·2004
Initial phase I study of XR5944, a novel DNA and RNA targeting agent
Journal of Clinical Oncology·2004· 2 cited
page 1 of 4Next →

Frequent Co-authors

Stan B. Kaye(4), J Cassidy(4), James Paul(4), A.N. Harnett(4), S.B. Kaye(4), Kukizo Miyamoto(3), Greg G. Hillebrand(3), Daniel P. Hannon(3), C Berge(3), A Setanoians(3), J Cassidy(3), Peter D. Wilson(3), David Kerr(3), Richard L. Anderson(3), James F. McBride(3), Howard L. McLeod(3), R. K. Chatterjee(2), Lawrence R. Robinson(2), J. Li(2), Marien Alet Graham(2)